Vinorelbine ditartrate (KW-2307) is a natural alkaloid and an anti-mitotic agent. Vinorelbine ditartrate has anti-tumor activity, inhibiting cell proliferation and inducing apoptosis.

Anti-mitotic:1.25 nM

METHODS: Human lung cancer cells NCI-H460 and A549 were treated with Vinorelbine ditartrate (0.01-10 µM) and DT-13 (10 µM) for 48 h. Cell viability was measured by MTT assay.
RESULTS: DT-13 significantly increased the cytotoxicity of Vinorelbine on NCI-H460 and A549 cells. The drug-drug interaction between DT-13 and NVB was calculated by combinatorial index (CI) value, which indicated that the DT-13/Vinorelbine combination therapy showed strong synergistic effects in NSCLC cells. [1]
METHODS: APC+ or APC- U2OS cells were treated with Vinorelbine ditartrate (1-50 µg/mL) for 4 h. Apoptosis was detected by Flow cytometry.
RESULTS: Vinorelbine-induced cell death was more pronounced in APC-deficient cells, suggesting that the number of aCasp3-containing cells increased after 4 h of treatment with a certain concentration of Vinorelbine. This rapid response to Vinorelbine suggests that death is not associated with mitotic arrest. [2]

METHODS: To assay antitumor activity in vivo, vinorelbine ditartrate (1-10 mg/kg, i.v.) and DT-13 (1.25 mg/kg, by gavage) were administered to BALB/c athymic nude mice bearing NCI-H460 xenografts once daily for three weeks.
RESULTS: Treatment with Myricetin or cisplatin alone moderately inhibited tumor growth, but the combination treatment inhibited tumor growth more significantly than Myricetin or cisplatin alone. [1]